These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3590295)

  • 1. Immune hemolysis by isohemagglutinins in factor IX concentrates.
    Ragni MV; Spero JA; Larson P; Ramsey G; Lewis JH
    Transfusion; 1987; 27(3):292-3. PubMed ID: 3590295
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemophilia, a changed picture].
    Breederveld C; ten Cate JW; Sixma JJ; Veltkamp JJ
    Ned Tijdschr Geneeskd; 1976 Jan; 120(2):69-70. PubMed ID: 1250448
    [No Abstract]   [Full Text] [Related]  

  • 3. Factor VIII and factor IX concentrates in surgery in hemophilia.
    Wolman IJ
    JAMA; 1971 Feb; 215(8):1328. PubMed ID: 5107574
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: Concentrates of clotting-factor IX.
    Mannucci PM; Bader R; Ruggeri ZM
    Lancet; 1976 Jan; 1(7949):41. PubMed ID: 54544
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of facoor VIII and factor IX concentrates during surgery.
    George JN; Breckenridge RT
    JAMA; 1970 Nov; 214(9):1673-6. PubMed ID: 5536529
    [No Abstract]   [Full Text] [Related]  

  • 7. Animal models of inhibitors.
    Reipert B; Arruda V; Lillicrap D
    Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic factor replacement in hemophilia.
    Carcao MD; Aledort L
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acid.
    Agrawal BL; Zelkowitz L; Hletko P
    J Pediatr; 1981 Jun; 98(6):931-3. PubMed ID: 7229796
    [No Abstract]   [Full Text] [Related]  

  • 12. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvements in factor concentrates.
    Lillicrap D
    Curr Opin Hematol; 2010 Sep; 17(5):393-7. PubMed ID: 20613509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of hemophilia.
    Kessler CM
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):184-7. PubMed ID: 18391917
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of hemophilia B with PPSB].
    Loeliger EA; Mattern MJ; Hensen A; Hemker HC
    Blut; 1968 Feb; 16(5):289-97. PubMed ID: 5647965
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the Treatments for Hemophilia.
    Guelcher CJ
    J Infus Nurs; 2016; 39(4):218-24. PubMed ID: 27379680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
    Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
    J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agarose gel method: its usefulness in assaying factor VIII inhibitors, evaluating treatment and suggesting a mechanism of action for factor IX concentrates.
    Coots MC; Glueck HI; Miller MA
    Br J Haematol; 1985 Aug; 60(4):735-50. PubMed ID: 3927972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.